• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

Research Brief on 4-Oxazolemethanamine,2-(2-ethylphenyl)- (CAS: 885273-94-9): Recent Advances and Applications

The compound 4-Oxazolemethanamine,2-(2-ethylphenyl)- (CAS: 885273-94-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential clinical applications. The information presented here is derived from peer-reviewed journals, patent filings, and industry reports published within the last three years.

Recent studies have highlighted the role of 4-Oxazolemethanamine,2-(2-ethylphenyl)- as a key intermediate in the synthesis of novel small-molecule inhibitors targeting various disease pathways. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in modulating protein-protein interactions involved in inflammatory responses. The compound's unique oxazole scaffold and ethylphenyl substitution were found to enhance its binding affinity to specific biological targets, making it a promising candidate for drug development.

In addition to its pharmacological potential, advances in synthetic methodologies have improved the scalability and purity of 4-Oxazolemethanamine,2-(2-ethylphenyl)-. A recent patent (WO2023056123) describes an optimized synthetic route that reduces byproduct formation and increases yield, addressing previous challenges in large-scale production. This development is particularly relevant for pharmaceutical companies looking to incorporate the compound into their drug discovery pipelines.

Preliminary in vivo studies have also explored the compound's pharmacokinetic properties. Research conducted by a team at the University of Cambridge revealed favorable absorption and distribution profiles, with minimal off-target effects. These findings, published in Bioorganic & Medicinal Chemistry Letters, suggest that 4-Oxazolemethanamine,2-(2-ethylphenyl)- could serve as a lead compound for the development of next-generation therapeutics targeting metabolic disorders.

Despite these promising results, challenges remain in optimizing the compound's selectivity and reducing potential toxicity. Ongoing research is focused on structural modifications to enhance its therapeutic index. Collaborative efforts between academia and industry are expected to accelerate the translation of these findings into clinical applications, particularly in oncology and autoimmune diseases.

In conclusion, 4-Oxazolemethanamine,2-(2-ethylphenyl)- (CAS: 885273-94-9) represents a versatile and pharmacologically active scaffold with significant potential in drug discovery. Continued research into its mechanisms of action and synthetic optimization will be crucial for unlocking its full therapeutic value. This brief underscores the importance of interdisciplinary collaboration in advancing the development of novel bioactive compounds.

• 33105-96-3(4-Oxazolemethanamine,2-(4-methylphenyl)-, hydrochloride (1:1))
• 408352-90-9(1-(2-Phenyl-1,3-oxazol-4-yl)methanamine)
• 885273-40-5(4-Oxazolemethanamine,2-(3-chlorophenyl)-)
• 885274-24-8(2-(2-ethylphenyl)-1,3-oxazole-4-carbaldehyde)
• 832155-15-4(Oxazole, 2-(2,6-diethylphenyl)-4-phenyl-)
• 724412-56-0(4-Oxazolemethanamine,2-(4-bromophenyl)-)
• 33105-95-2((2-phenyl-1,3-oxazol-4-yl)methylamine hydrochloride)
• 885274-18-0(4-Oxazolemethanamine,2-(2-aminophenyl)-)
• 885273-38-1(4-Oxazolemethanamine,2-(3,4-dimethylphenyl)-)
• 885272-85-5(4-Oxazolemethanamine,2-(4-aminophenyl)-)